To include your compound in the COVID-19 Resource Center, submit it here.

Syntimmune reports Phase Ia data for autoimmune disease candidate

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE